Karl Swedberg

Aug 30, 2024 | jamanetwork.com | Henri Lu |Brian Claggett |Milton Packer |Karl Swedberg

Key PointsQuestion  What are the effects of sacubitril/valsartan on hospitalizations of any cause in patients with heart failure (HF)? Findings  In this post hoc pooled analysis of the PARADIGM-HF and PARAGON-HF randomized clinical trials including 13 194 patients, sacubitril/valsartan significantly reduced the risk of all-cause hospitalization, primarily driven by lower rates of cardiac and pulmonary hospitalization.